Panobinostat is a histone deacetylase (HDAC) inhibitor. When used in combination with bortezomib and dexamethasone, it provides a treatment option for patients with refractory multiple myeloma.
Indications of Panobinostat
Relapsed Multiple Myeloma
Used in combination with bortezomib and dexamethasone for patients with multiple myeloma who have previously received at least 2 treatment regimens (including bortezomib and immunomodulatory agents).
This indication is approved under accelerated approval based on progression-free survival (PFS), and subsequent confirmatory trials are required to verify clinical benefits.
Specifications and Properties of Panobinostat
Dosage Form and Content
10mg Capsule: Light green opaque capsule, with black "LBH10mg" printed on the cap, containing white to off-white powder.
15mg Capsule: Orange opaque capsule, with black "LBH15mg" printed on the cap, containing white to off-white powder.
20mg Capsule: Red opaque capsule, with black "LBH20mg" printed on the cap, containing white to off-white powder.
Excipient Components
Contains inactive ingredients such as magnesium stearate, mannitol, and microcrystalline cellulose. The capsule shell contains gelatin, iron oxide colorants (e.g., FD&C Blue No. 1 for 10mg capsules, yellow iron oxide for 15mg capsules), and titanium dioxide.
Must be swallowed whole; do not open, crush, or chew.
Storage Methods of Panobinostat
Environmental Requirements
Store at 20°C ~ 25°C (68°F ~ 77°F). Short-term exposure to 15°C ~ 30°C (59°F ~ 86°F) is allowed.
Must be kept in the original aluminum foil blister packaging (with built-in desiccant) to protect from light and moisture.
Precautions for Use
When opening the blister, only puncture the recess where the capsule is located; avoid contact with the desiccant bag.
The contents of the capsule are cytotoxic drugs; avoid direct contact with skin or mucous membranes. If contact occurs, rinse thoroughly with clean water immediately.
Discard expired or unused medications to prevent accidental access by children.
